Patents by Inventor Hyuk Woo Lee
Hyuk Woo Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240148769Abstract: The present invention relates to a pharmaceutical composition for preventing or treating coronavirus disease 19 (COVID-19) and specifically, to a pharmaceutical composition containing a carbocyclic nucleoside derivative represented by Chemical Formula A-1 or A-2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 17, 2022Publication date: May 9, 2024Applicant: FUTURE MEDICINE CO., LTD.Inventors: Hyuk Woo LEE, Seo Hyun SON, Ji Yoon KANG, Hyu Jeong JANG, Seong Wook SEO
-
Patent number: 11964161Abstract: Disclosed is a plasma generator. The plasma generator may include a gripping portion including at least one interface unit configured to receive an input from a user; a head portion including a plasma generating portion configured to generate the plasma; a first cartridge configured to detachably couple at a first end of the head portion and generate the plasma over a predetermined region; and a light irradiation portion provided at a second end of the head portion.Type: GrantFiled: August 4, 2023Date of Patent: April 23, 2024Assignee: GCS Co., Ltd.Inventors: Chang Sik Kim, Tae Yong Kim, Myeong Woo Kim, Hyuk Namgoong, Ha Yun Lee
-
Patent number: 11961903Abstract: A power semiconductor device includes a semiconductor layer of silicon carbide (SiC), at least one trench that extends in one direction, a gate insulating layer disposed on at least an inner wall of the at least one trench, at least one gate electrode layer disposed on the gate insulating layer, a drift region disposed in the semiconductor layer at least on one side of the at least one gate electrode layer, a well region disposed in the semiconductor layer to be deeper than the at least one gate electrode layer, a source region disposed in the well region, and at least one channel region disposed in the semiconductor layer of one side of the at least one gate electrode layer between the drift region and the source region.Type: GrantFiled: May 25, 2021Date of Patent: April 16, 2024Assignee: HYUNDAI MOBIS CO., LTD.Inventors: Jeong Mok Ha, Hyuk Woo, Sin A Kim, Tae Youp Kim, Ju Hwan Lee, Min Gi Kang, Tae Yang Kim
-
Patent number: 11953958Abstract: A display includes: a display panel; and a panel bottom sheet disposed below the display panel, the panel bottom sheet including: a first heat dissipation layer; a second heat dissipation layer over the first heat dissipation layer, including a first opening formed completely through the second heat dissipation layer in a thickness direction; a heat dissipation coupling interlayer between the first heat dissipation layer and the second heat dissipation layer, and a heat dissipation substrate on the second heat dissipation layer.Type: GrantFiled: December 12, 2022Date of Patent: April 9, 2024Assignee: Samsung Display Co., Ltd.Inventors: Kang Woo Lee, Boo Kan Ki, June Hyoung Park, Sun Hee Oh, Dong Hyeon Lee, Jeong In Lee, Hyuk Hwan Kim, Seong Sik Choi
-
Patent number: 11780810Abstract: A preparation method according to the present invention makes it possible to industrially produce large amounts of highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield by use of commercially available reagents and solvents. In addition, the use of novel intermediates according to the present invention makes it possible to produce highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield.Type: GrantFiled: January 7, 2022Date of Patent: October 10, 2023Inventors: Jae Hong Kweon, Eun Sun Kim, Hyuk Woo Lee, Dong Hyun Ko, Chae Young Ryu, Kwang Do Choi, SeungPyeong Heo
-
Publication number: 20230095356Abstract: The present disclosure relates to a pharmaceutical composition, an oral administration agent and an eye drop for preventing or treating retinal diseases or optic nerve diseases including the compound represented by the Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient and the pharmaceutical composition, the oral administration agent and the eye drop can effectively prevent or treat retinal disease or optic nerve disease.Type: ApplicationFiled: July 18, 2022Publication date: March 30, 2023Applicant: FUTURE MEDICINE CO., LTD.Inventors: Jae Wook YANG, Jee Young KIM, Hyuk Woo LEE, Chong-Woo PARK, Mi Ra YU, Ji Youn LEE, Bo Mi PARK
-
Patent number: 11524968Abstract: The present invention provides a novel compound having a protein kinase inhibition activity, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to the present invention show a protein kinase inhibition activity, thus being effective in preventing or treating diseases related to protein kinase, such as cancer, autoimmune disease, neurological disease, metabolic disease, infection or the like.Type: GrantFiled: October 17, 2018Date of Patent: December 13, 2022Assignee: HK inno.N CorporationInventors: Hyuk Woo Lee, Mi Kyung Ji, Seung Chan Kim, Ha Na Yu, Soo Yeon Jung, Ji-Yeon Park, Ye-Lim Lee, Ho-Youl Lee, So Young Ki, Dongkyu Kim, Myeongjoong Kim
-
Publication number: 20220127230Abstract: A preparation method according to the present invention makes it possible to industrially produce large amounts of highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield by use of commercially available reagents and solvents. In addition, the use of novel intermediates according to the present invention makes it possible to produce highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield.Type: ApplicationFiled: January 7, 2022Publication date: April 28, 2022Inventors: Jae Hong Kweon, Eun Sun Kim, Hyuk Woo Lee, Dong Hyun Ko, Chae Young Ryu, Kwang Do Choi, SeungPyeong Heo
-
Patent number: 11254641Abstract: A preparation method according to the present invention makes it possible to industrially produce large amounts of highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield by use of commercially available reagents and solvents. In addition, the use of novel intermediates according to the present invention makes it possible to produce highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield.Type: GrantFiled: December 7, 2018Date of Patent: February 22, 2022Assignee: HK inno.N CorporationInventors: Jae Hong Kweon, Eun Sun Kim, Hyuk Woo Lee, Dong Hyun Ko, Chae Young Ryu, Kwang Do Choi, SeungPyeong Heo
-
Publication number: 20210361690Abstract: The present invention relates to a pharmaceutical composition, an oral administration agent and an eye drop for preventing or treating retinal diseases or optic nerve diseases comprising the compound represented by the Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient and the pharmaceutical composition, the oral administration agent and the eye drop can effectively prevent or treat retinal disease or optic nerve disease.Type: ApplicationFiled: November 29, 2018Publication date: November 25, 2021Applicant: FUTURE MEDICINE CO., LTD.Inventors: Jae Wook YANG, Jee Young KIM, Hyuk Woo LEE, Chong-Woo PARK, Mi Ra YU, Ji Youn LEE, Bo Mi PARK
-
Publication number: 20210171544Abstract: The present invention provides a novel compound having a protein kinase inhibition activity, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to the present invention show a protein kinase inhibition activity, thus being effective in preventing or treating diseases related to protein kinase, such as cancer, autoimmune disease, neurological disease, metabolic disease, infection or the like.Type: ApplicationFiled: October 17, 2018Publication date: June 10, 2021Inventors: Hyuk Woo Lee, Mi Kyung Ji, Seung Chan Kim, Ha Na Yu, Soo Yeon Jung, Ji-Yeon Park, Ye-Lim Lee, Ho-Youl Lee, So Young KI, Dongkyu Kim, Myeongjoong Kim
-
Publication number: 20210107873Abstract: A preparation method according to the present invention makes it possible to industrially produce large amounts of highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield by use of commercially available reagents and solvents. In addition, the use of novel intermediates according to the present invention makes it possible to produce highly pure optically active tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate in high yield.Type: ApplicationFiled: December 7, 2018Publication date: April 15, 2021Inventors: Jae Hong Kweon, Eun Sun Kim, Hyuk Woo Lee, Dong Hyun Ko, Chae Young Ryu, Kwang Do Choi, SeungPyeong Heo
-
Patent number: 9908870Abstract: The present invention relates to a novel crystalline form of a benzimidazole derivative and a preparation method thereof. The novel crystalline form according to the present invention is hardly changed chemically and/or physically under a long-term photo-stressed condition, has a low hygroscopicity, and has an extremely low static-electricity-inducing capability, thus being advantageous for formulation, and due to the excellent stability of the crystal form itself, it is very useful for long-term storage of the compound.Type: GrantFiled: November 18, 2015Date of Patent: March 6, 2018Assignee: CJ HEALTHCARE CORPORATIONInventors: Young Ju Kim, Eun Sun Kim, Ji Yun Lee, Hyuk Woo Lee, Jae Hong Kweon, Sung Ah Lee, Kwang Do Choi, Dong Hyun Ko, Seung Pyeong Heo
-
Publication number: 20180009791Abstract: The present invention relates to a novel crystalline form of a benzimidazole derivative and a preparation method thereof. The novel crystalline form according to the present invention is hardly changed chemically and/or physically under a long-term photo-stressed condition, has a low hygroscopicity, and has an extremely low static-electricity-inducing capability, thus being advantageous for formulation, and due to the excellent stability of the crystal form itself, it is very useful for long-term storage of the compound.Type: ApplicationFiled: November 18, 2015Publication date: January 11, 2018Inventors: Young Ju KIM, Eun Sun KIM, Ji Yun LEE, Hyuk Woo LEE, Jae Hong KWEON, Sung Ah LEE, Kwang Do CHOI, Dong Hyun KO, Seung Pyeong HEO
-
Publication number: 20140371244Abstract: The present invention relates to a method by use of a pharmaceutical composition for preventing or treating inflammatory disease, colorectal cancer and prostate cancer, which contains an A3 adenosine receptor agonist, 2-chloro-N6-(3-iodobenzyl)-4?-thioadenosine-5?-N-methyluronamide (thio-Cl-IB-MECA), N6-(3-iodobenzyl)-4?-thioadenosine-5?-N-methyluronamide (thio-IB-MECA), or a pharmaceutically acceptable salt thereof. The pharmaceutical composition of the invention is significantly less toxic than conventional A3 adenosine agonists, and thus is useful for prevention or treatment of inflammatory disease. In addition, it more selectively inhibits the growth of androgen receptor-dependent or independent prostate cancer cells than other A3 adenosine receptor agonists and thus is useful for prevention or treatment of colorectal cancer or prostate cancer.Type: ApplicationFiled: February 28, 2014Publication date: December 18, 2014Applicant: Ewha University - Industry Collaboration FoundationInventors: Lak Shin JEONG, Sang Kook LEE, Hwa Jin CHUNG, Hyuk Woo LEE
-
Patent number: 8716304Abstract: The present invention relates to a method for preparation of MLN4924 as an E1 activating inhibitor, and more specifically, to a method for efficient and stereoselective preparation of MLN4924 by means of key steps involving stereoselective reduction of cyclopentenone with isopropylidene, regioselective cleavage of isopropylidene moiety, and synthesis of cyclic sulfate.Type: GrantFiled: March 20, 2012Date of Patent: May 6, 2014Assignee: EWHA University—Industry Collaboration FoundationInventors: Lak Shin Jeong, Hyuk Woo Lee
-
Publication number: 20120330013Abstract: The present invention relates to a method for preparation of MLN4924 as an E1 activating inhibitor, and more specifically, to a method for efficient and stereoselective preparation of MLN4924 by means of key steps involving stereoselective reduction of cyclopentenone with isopropylidene, regioselective cleavage of isopropylidene moiety, and synthesis of cyclic sulfate.Type: ApplicationFiled: March 20, 2012Publication date: December 27, 2012Applicant: Ewha University - Industry Collaboration FoundationInventors: Lak Shin JEONG, Hyuk Woo Lee
-
Publication number: 20120322815Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory disease, colorectal cancer and prostate cancer, which contains an A3 adenosine receptor agonist, 2-chloro-N6-(3-iodobenzyl)-4?-thioadenosine-5?-N-methyluronamide (thio-Cl-IB-MECA), N6-(3-iodobenzyl)-4?-thioadenosine-5?-N-methyluronamide (thio-IB-MECA), or a pharmaceutically acceptable salt thereof. The pharmaceutical composition of the invention is significantly less toxic than conventional A3 adenosine agonists, and thus is useful for prevention or treatment of inflammatory disease. In addition, it more selectively inhibits the growth of androgen receptor-dependent or independent prostate cancer cells than other A3 adenosine receptor agonists and thus is useful for prevention or treatment of colorectal cancer or prostate cancer.Type: ApplicationFiled: December 16, 2010Publication date: December 20, 2012Applicant: EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATIONInventors: Lak Shin Jeong, Sang Kook Lee, Hwa Jin Chung, Hyuk Woo Lee